Perenostobart

派瑞苏拜单抗

Report date: 2024/05/19 20:00:11

Base Information

Drug NamePerenostobart
Drug Alias NameSRF-617
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionT lymphocytes stimulantsEctonucleoside triphosphate diphosphohydrolase 1 inhibitors
TargetsEctonucleoside triphosphate diphosphohydrolase 1
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSurface Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesCoherus Biosciences IncSurface Oncology Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A